Document is current
Any future updates will be listed below
-
Authors
Collier, Ann E. https://orcid.org/0000-0003-3410-3238
Hilz, Stephanie
Chibly, Alejandro M. https://orcid.org/0000-0001-7747-4990
Duan, Chunzhe
Pasquina, Lincoln W. https://orcid.org/0009-0009-5461-9777
Sun, Xiaopeng
Chavez-MacGregor, Mariana https://orcid.org/0000-0002-7189-0763
Bardia, Aditya https://orcid.org/0000-0003-4885-1157
Martín, Miguel https://orcid.org/0000-0001-9237-3231
Lim, Elgene https://orcid.org/0000-0001-8065-8838
Sohn, Joohyuk https://orcid.org/0000-0002-2303-2764
Pérez-Moreno, Pablo Diego
Fernando, Tharu M. https://orcid.org/0000-0001-9672-6428
Moore, Heather M.
-
Funding
Funding for this research was provided by:
The study was sponsored by F. Hoffmann-La Roche Ltd
- License Information
-
More Information
Article History
Received: 9 July 2025
Accepted: 16 February 2026
First Online: 12 March 2026
Competing interests
: The study was sponsored by F. Hoffmann-La Roche Ltd. The authors declare the following competing interests: A.E.C., S.H., A.M.C., P.D.P.-M., and H.M.M. are employees of Genentech, Inc. and hold stock in F. Hoffmann-La Roche Ltd. C.D. is an employee of Roche (China) Holding Ltd. and holds stock in F. Hoffmann-La Roche Ltd. and Bristol Myers Squibb. L.W.P. is an employee of Foundation Medicine and holds stock in Roche Holdings AG. M.CM. reports consulting fees from Novartis, AstraZeneca, and Lilly; honoraria from Exact Sciences; travel support from Novartis and AstraZeneca; advisory board participation for AstraZeneca and Roche/Genentech; and board membership for Legacy Community Health, The Hope Foundation, and ASCO. A.B. reports grants and personal fees from Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, Daiichi Pharma/AstraZeneca, Alyssum, and Eli Lilly. M.M. reports honoraria and advisory fees from Roche/Genentech, Lilly, Pfizer, Novartis, Pierre Fabre, Seagen, AstraZeneca, and Daiichi-Sankyo; and research funding from Novartis, Roche, and Puma Biotechnology. E.L. reports institutional advisory/steering committee roles and research funding from AstraZeneca, Gilead, Lilly, MSD, Novartis, Pfizer, and Roche; royalties from Walter and Eliza Hall Institute; and leadership roles at Breast Cancer Trials Australia, Garvan Institute, St Vincent’s Hospital, and UNSW. J.S. reports institutional research funding from Seagen, MSD, Roche, Pfizer, Novartis, AstraZeneca, Lilly, GSK, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Qurient, Dragonfly, Eikon, Gilead, Celcuity, BMS, HLB Life Science, Sermonix, Olema, Hanmi, Ildong, and Samyang; and family stock ownership in Daiichi Sankyo. X.S. declares no competing interests.
